6th Annual Cannabinoid-Derived Drug Development Summit

Welcome to the 6th Annual Cannabinoid-Derived Drug Development Summit: Fundamental Understanding of Cannabinoid Translation. This premier event brings together preclinical and clinical scientists, R&D leaders, and drug developers in the field of cannabinoid research. With a focus on navigating new FDA regulatory guidance, discovering novel cannabinoids, and translating cannabinoid research from preclinical models into clinical trials, this summit is at the forefront of advancements in cannabinoid-derived drug development.

Leading industry players such as Jazz Pharmaceuticals, GB Sciences, Alterola, Avicanna, and Roche will be present to collaborate and address key challenges in the field. These challenges include understanding drug metabolism and pharmacokinetics (DMPK), tackling the clinical placebo effect, and enhancing translational potency.

Attendees will have the opportunity to delve into the latest innovations in cannabinoid research, particularly in the areas of neurology and pain, cardiometabolic disorders, dermatology, oncology, and more. The summit will feature discussions on in vivo and in vitro translation of cannabinoids, optimizing bioavailability, dosage and delivery methods, and selecting appropriate clinical trial outcomes.

With over 80 scientists in attendance, this event offers a unique platform for sharing knowledge and insights, ultimately aiming to establish FDA-accepted and patient-compliant dosage regimes for CBD therapeutics. The intimate nature of the summit encourages in-depth discussions and fosters collaborations that can drive the development of effective cannabinoid-derived drugs.

Join us at the 6th Annual Cannabinoid-Derived Drug Development Summit to stay at the forefront of this rapidly evolving field and contribute to the advancement of cannabinoid therapeutics.